Search research articles
Contact Us
Filters
Showing results (31-40 of 120) with videos related to
Page
of 12
Sort By:
Joint Commission Journal on Quality and Patient Safety
|
February 8, 2022
Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic
Erika Leemann Price, Jack Ansell
Current Hematology Reports
|
September 1, 2005
Cancer and thrombosis
Elisabeth M Battinelli, Jack Ansell
Expert Review of Cardiovascular Therapy
|
December 22, 2007
Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management
Katherine W Phillips, Jack Ansell
Thrombosis and Haemostasis
|
January 12, 2010
The clinical implications of new oral anticoagulants: will the potential advantages be achieved?
Katherine W Phillips, Jack Ansell
Current Opinion in Hematology
|
June 25, 2009
Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change
Jennifer Carreiro Zikria, Jack Ansell
Evidence-Based Medicine
|
April 5, 2011
Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications
David J Rosenberg, Jack Ansell
Journal of Thrombosis and Haemostasis : JTH
|
May 22, 2026
A Light in the Dark - Reframing DOAC Pharmacokinetics and Pharmacodynamics for Near-Patient Decision-Making
Joseph R Shaw, Jack Ansell
Hospital Practice (1995)
|
October 23, 2012
Target-specific oral anticoagulants for stroke prevention in patients with atrial fibrillation: real-world considerations
David J Rosenberg, Jack Ansell
Nature Reviews. Cardiology
|
February 29, 2012
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation
Katherine P Cabral, Jack Ansell
The Journal of the Michigan Dental Association
|
December 6, 2012
Kudos on anticoagulation issue
Randy Fenninger, Jack Ansell, Alan Brownstein
Page
of 12
Search research articles
Search
Showing results (31-40 of 120) with videos related to
Sort By:
Page
of 12
Joint Commission Journal on Quality and Patient Safety
|
February 8, 2022
Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic
Erika Leemann Price, Jack Ansell
Current Hematology Reports
|
September 1, 2005
Cancer and thrombosis
Elisabeth M Battinelli, Jack Ansell
Expert Review of Cardiovascular Therapy
|
December 22, 2007
Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management
Katherine W Phillips, Jack Ansell
Thrombosis and Haemostasis
|
January 12, 2010
The clinical implications of new oral anticoagulants: will the potential advantages be achieved?
Katherine W Phillips, Jack Ansell
Current Opinion in Hematology
|
June 25, 2009
Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change
Jennifer Carreiro Zikria, Jack Ansell
Evidence-Based Medicine
|
April 5, 2011
Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications
David J Rosenberg, Jack Ansell
Journal of Thrombosis and Haemostasis : JTH
|
May 22, 2026
A Light in the Dark - Reframing DOAC Pharmacokinetics and Pharmacodynamics for Near-Patient Decision-Making
Joseph R Shaw, Jack Ansell
Hospital Practice (1995)
|
October 23, 2012
Target-specific oral anticoagulants for stroke prevention in patients with atrial fibrillation: real-world considerations
David J Rosenberg, Jack Ansell
Nature Reviews. Cardiology
|
February 29, 2012
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation
Katherine P Cabral, Jack Ansell
The Journal of the Michigan Dental Association
|
December 6, 2012
Kudos on anticoagulation issue
Randy Fenninger, Jack Ansell, Alan Brownstein
Page
of 12